Analysis
City Therapeutics set terms for its IPO, offering 9.7 million shares at $17 to $19 each to raise an estimated $175 million, according to its S-1/A and IPOScoop's weekly calendar. The biotech is expected to start trading Friday, October 16, on Nasdaq under the ticker CTY, led by underwriters Goldman Sachs, Jefferies, Stifel and Oppenheimer & Co.
City Therapeutics is one of just two names on this week's US IPO calendar, alongside Iambic Therapeutics, which raised its own target from roughly $100 million to $150 million and is expected to price a day earlier, on Thursday. Iambic's deal is led by J.P. Morgan, Jefferies, BofA Securities and Citigroup -- a different bank syndicate, which makes the two IPOs a useful same-week comparison for how investors are pricing clinical-stage biotech right now.
The pairing extends a pattern Pulse has tracked through October: smaller, clinical-stage biotech IPOs are pricing and trading even as larger, capital-intensive listings stall or withdraw. Nvidia-backed Firmus pulled its roughly $31 billion data-center IPO on market-turbulence grounds just days earlier, while two smaller biotechs, TRex Bio and Retension Pharmaceuticals, priced a combined $161.7 million anyway.
At the midpoint of its range, City's estimated raise would be modestly larger than Iambic's targeted deal and well above the combined take from TRex Bio and Retension Pharmaceuticals, the two smaller biotechs that priced the same week Firmus withdrew. That relative sizing matters for gauging investor appetite: underwriters generally won't set a wider, higher-dollar range like City's unless they already have book-building demand to support it, which is itself a signal distinct from the deal's eventual day-one trading performance.
IPOScoop's listing doesn't detail City Therapeutics' pipeline or lead program, so the company's underlying science isn't yet independently verifiable from this filing data alone -- the estimated proceeds figure is also IPOScoop's projected deal size based on the midpoint price and share count, not a confirmed final number, which can still move when the deal actually prices.
Watch Thursday's Iambic pricing as the near-term signal for how City's own deal gets priced Friday, and whether either deal prices above, at, or below its range -- the clearest real-time read on biotech IPO demand available this week.
